Dizhe E B, Akifiev B N, Missul B V, Orlov S V, Kidgotko O V, Sukonina V E, Denisenko A D, Perevozchikov A P
Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, 197376 Russia.
Biochemistry (Mosc). 2001 Jan;66(1):55-61. doi: 10.1023/a:1002881612906.
With the goal of developing non-viral techniques for exogenous gene delivery into mammalian cells, we have studied receptor-mediated gene transfer using complexes of plasmid DNA and galactosylated poly-L-lysine, poly(L-Lys)Gal. To evaluate the optimal parameters for efficient gene transfer into human hepatoma HepG2 cells by the DNA-poly(L-Lys)Gal complexes, the bacterial reporter genes lacZ and cat were used. Examination of the reporter gene expression level showed that the efficiency of DNA delivery into the cells depends on the structure of DNA--poly(L-Lys)Gal complexes formed at various ionic strength values. The efficiency of DNA transfer into the cells also depends on DNA/poly(L-Lys)Gal molar ratio in the complexes. Plasmid vector carrying human apolipoprotein A-I (apoA-I) gene was injected as its complex with poly(L-Lys)Gal into rat tail vein. Some level of ApoA-I was detected in the serum of the injected rats. Also, the human apoA-I-containing plasmid was found to be captured specifically by the rat liver cells and transported into the cell nuclei, where it can persist as an episome-like structure for at least a week. After repeated injections of DNA--poly(L-Lys)Gal complexes, the level of human ApoA-I in rat serum increases, probably, due to accumulation of functional human apoA-I gene in the liver cell nuclei. The data seem to be useful for the development of non-viral approaches to gene therapy of cardiovascular diseases.
为了开发将外源基因导入哺乳动物细胞的非病毒技术,我们研究了使用质粒DNA与半乳糖基化聚-L-赖氨酸(聚(L-赖氨酸)Gal)复合物进行受体介导的基因转移。为了评估通过DNA-聚(L-赖氨酸)Gal复合物将基因有效导入人肝癌HepG2细胞的最佳参数,使用了细菌报告基因lacZ和cat。对报告基因表达水平的检测表明,DNA导入细胞的效率取决于在不同离子强度值下形成的DNA-聚(L-赖氨酸)Gal复合物的结构。DNA转入细胞的效率还取决于复合物中DNA/聚(L-赖氨酸)Gal的摩尔比。携带人载脂蛋白A-I(apoA-I)基因的质粒载体与其与聚(L-赖氨酸)Gal的复合物一起注入大鼠尾静脉。在注射大鼠的血清中检测到了一定水平的ApoA-I。此外,发现含人apoA-I的质粒被大鼠肝细胞特异性捕获并转运到细胞核中,在那里它可以作为类似附加体的结构持续存在至少一周。多次注射DNA-聚(L-赖氨酸)Gal复合物后,大鼠血清中人ApoA-I的水平升高,这可能是由于功能性人apoA-I基因在肝细胞核中积累所致。这些数据似乎对开发心血管疾病基因治疗的非病毒方法有用。